Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

SNSS 0.500 -0.005 (-0.97%)
price chart
Option Market: Sunesis Pharmaceuticals Inc Risk Hits An Extreme High
This is a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) .
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) Stock Technicals at Critical ...
This is a technical analysis stock rating for Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) . The company has a three bull technical rating which indicates an inflection point.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): Sell-Side Ratings and Company ...
As companies start to report earnings, investors and analysts will be watching to see if the company meets or beats predictions after the next release.
Stock Up Nicely This Week: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Investors Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) are heading into the weekend on a positive note as the stock provided some gains this week moving 0.02% over the past 5 trading days.
Sunesis Pharmaceuticals Incorporated New (NASDAQ:SNSS) Shorted Shares ...  Press Telegraph
Equity Roundup: Stock Performance Focus on Sunesis Pharmaceuticals, Inc ...
During the most recent trading session, shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) changed +1.600%. Street analysts that track the company are anticipating the stock to go to $2.500 within the next year.
Sunesis Pharmaceuticals Inc. Realized Volatility Hits Extreme Level
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) . We examine the little used gem of daily stock volatilty over ...
New VP Could Help Save Shareholders In Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is still soaked in losses and the management can be seen struggling to get the company out of the red.
Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of updated results from an ongoing Phase 1b/2University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with ...
Sunesis Pharmaceuticals Adds 6% After Presenting Data from Frontline Elderly ...  Sonoran Weekly Review
Stock Moving Lower for the Month; Investor Update on Sunesis Pharmaceuticals ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares have slid down over the previous month, which may be worrying some investors.
Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Appoints Linda ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development.